Trial Profile
A multicenter, single armed, phase 1b trial of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Alveolar soft part sarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 08 Jun 2022 Results published in the Clinical Cancer Research
- 24 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.